What does this research mean for the field?

Adjunctive anti-VEGF therapy combined with standard ablative treatment in Coats disease significantly reduces the number of treatment sessions required to achieve quiescence without increasing the risk of tractional retinal detachment or altering final visual acuity. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the efficacy and safety of adjunctive intravitreal anti-VEGF therapy combined with standard ablative treatment compared to ablation alone in Coats disease.

September 10, 2026Retina

Adjuvant Anti-VEGF Therapy During Ablative Treatment for Coats Disease: A Systematic Review and Meta-Analysis

View Full Paper

Ask AI

Bookmark

Authors

CZCharles Zhang NLNicholas Leung BSBaltaj Sandhur

Discussion

Member takes

Overview

Systematic review and meta-analysis reveals reduced treatment sessions with adjuvant anti-VEGF in Coats disease, indicating lower procedural burden without increasing retinal detachment risk.

Key Points

To evaluate the efficacy and safety of adjunctive intravitreal anti-VEGF therapy combined with standard ablative treatment compared to ablation alone in Coats disease.
Searched PubMed, Embase, and SCOPUS for comparative studies evaluating ablative therapy alone versus combination therapy with anti-VEGF.
Analyzed five retrospective studies encompassing 218 eyes (136 receiving ablation alone and 82 receiving adjuvant anti-VEGF).
Adjunctive anti-VEGF significantly lowered the number of treatment sessions required to reach quiescence (MD 0.47 sessions, 95% CI 0.10–0.85, p = 0.01).
No significant differences occurred in final best-corrected visual acuity (MD 0.20, 95% CI -0.20 to 0.59, p = 0.33; I² = 23%) or phthisis rates between cohorts.
The addition of anti-VEGF was not associated with a statistically significant increase in tractional retinal detachment (RR 2.64, 95% CI 0.34–20.30, p = 0.35).

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6aa27b3558559d80afc744bb https://doi.org/10.1097/iae.0000000000005008

View Full Paper

Ask AI

Bookmark

September 10, 2026Retina

Adjuvant Anti-VEGF Therapy During Ablative Treatment for Coats Disease: A Systematic Review and Meta-Analysis

View Full Paper

Ask AI

Bookmark

Authors

CZCharles Zhang NLNicholas Leung BSBaltaj Sandhur

Discussion

Member takes

Overview

Systematic review and meta-analysis reveals reduced treatment sessions with adjuvant anti-VEGF in Coats disease, indicating lower procedural burden without increasing retinal detachment risk.

Key Points

To evaluate the efficacy and safety of adjunctive intravitreal anti-VEGF therapy combined with standard ablative treatment compared to ablation alone in Coats disease.
Searched PubMed, Embase, and SCOPUS for comparative studies evaluating ablative therapy alone versus combination therapy with anti-VEGF.
Analyzed five retrospective studies encompassing 218 eyes (136 receiving ablation alone and 82 receiving adjuvant anti-VEGF).
Adjunctive anti-VEGF significantly lowered the number of treatment sessions required to reach quiescence (MD 0.47 sessions, 95% CI 0.10–0.85, p = 0.01).
No significant differences occurred in final best-corrected visual acuity (MD 0.20, 95% CI -0.20 to 0.59, p = 0.33; I² = 23%) or phthisis rates between cohorts.
The addition of anti-VEGF was not associated with a statistically significant increase in tractional retinal detachment (RR 2.64, 95% CI 0.34–20.30, p = 0.35).

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6aa27b3558559d80afc744bb https://doi.org/10.1097/iae.0000000000005008

View Full Paper

Ask AI

Bookmark